AZASAN (azathioprine) by Enterprise Therapeutics is nucleic acid synthesis inhibitors [moa]. Approved for active rheumatoid arthritis to reduce signs, symptoms, active rheumatoid arthritis (ra) to reduce signs and 2 more indications. First approved in 1999.
Drug data last refreshed 18h ago
Nucleic Acid Synthesis Inhibitors
Purine Antimetabolite
Worked on AZASAN at Enterprise Therapeutics? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Comparison of Azathioprine to Methotrexate in Combination Therapy With Adalimumab in Crohn's Disease: an Open-label Randomized Controlled Trial
Effect of JKB-122 on Prednisolone and Azathioprine Induced Remission in Autoimmune Hepatitis (AIH)
Bioequivalence of Azathioprine Suspension 10 mg/mL (Jayempi) Versus Azathioprine Tablet 50mg (Imurek®)
Azathioprine Based on Endoscopy After Clinical Remission in Moderate to Severe Ulcerative Colitis
Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy of Lupus Nephritis
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo